In another large cohort of 269 young patients with CN-AML, ID1 acts as an independent negative prognostic factor when the mutational status of CCAAT/enhancer-binding protein-alpha (CEBPA) is not considered. The gene discussed is CEBPA; the disease is acute myeloid leukemia.